We also examined the 1,500 most statistically significant SNPs from Stage 1 in the GIANT consortium (n=123,706 individuals of European ancestry)6. Of these, 1,390 were genotyped or imputed in GIANT and 1,328 had data for n>50,000 and a MAF>1%. We conducted a meta-analysis of Stages 1+2+3+GIANT in the same manner as described above. The three novel variants were also examined in the AGEN and RIKEN consortia7,8 and the Pediatric Research Consortium (PeRC) (see Supplementary Note).
